The World Health Organization will restart its trial of hydroxychloroquine after getting the all-clear from a safety review, its chief announced Wednesday.
The U.N. health body paused enrolling patients in the part of its Solidarity trial studying hydroxychloroquine last week. Officials cited a large, observational study in the Lancet — echoing smaller studies — that suggested the malaria and lupus medication increased the risk of heart disease and death. The Lancet study has since come under fire, with the prestigious medical journal issuing an “expression of concern” about various problems with the data collection and methods.
A safety monitoring committee looked at death rates in both the WHOs Solidarity trial and the U.K.s Recovery trial, which is also studying hydroxychloroquine, to see if they were different among patients taking that drug. The safety committee “recommended that there are no reasons to modify the trial protocol,” WHO Director General Tedros Adhanom Ghebreyesus said today.
The multinational panel overseeing the trial endorsed that finding and will “communicate with the principal investigators in theRead More – Source
The World Health Organization will restart its trial of hydroxychloroquine after getting the all-clear from a safety review, its chief announced Wednesday.
The U.N. health body paused enrolling patients in the part of its Solidarity trial studying hydroxychloroquine last week. Officials cited a large, observational study in the Lancet — echoing smaller studies — that suggested the malaria and lupus medication increased the risk of heart disease and death. The Lancet study has since come under fire, with the prestigious medical journal issuing an “expression of concern” about various problems with the data collection and methods.
A safety monitoring committee looked at death rates in both the WHOs Solidarity trial and the U.K.s Recovery trial, which is also studying hydroxychloroquine, to see if they were different among patients taking that drug. The safety committee “recommended that there are no reasons to modify the trial protocol,” WHO Director General Tedros Adhanom Ghebreyesus said today.
The multinational panel overseeing the trial endorsed that finding and will “communicate with the principal investigators in theRead More – Source
